Merck sleep aid Belsomra OK'd by FDA
This article was originally published in Scrip
Merck investors can rest easy over the company's sleep aid Belsomra (suvorexant), a first-of-its-kind product, now that the FDA has finally given its blessing to the medicine – with the firm winning approval to market the drug at the 5mg, 10mg, 15mg and 20mg doses.
You may also be interested in...
J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.